(19)
(11) EP 4 422 651 A2

(12)

(88) Date of publication A3:
15.06.2023

(43) Date of publication:
04.09.2024 Bulletin 2024/36

(21) Application number: 22888415.1

(22) Date of filing: 24.10.2022
(51) International Patent Classification (IPC): 
A61K 35/17(2015.01)
A61P 35/00(2006.01)
A61K 38/16(2006.01)
C07H 21/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/4632; A61K 39/4611; A61K 39/464486; C07K 14/7051
(86) International application number:
PCT/US2022/078597
(87) International publication number:
WO 2023/076863 (04.05.2023 Gazette 2023/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 25.10.2021 US 202163271368 P
15.11.2021 US 202163279527 P

(71) Applicant: Board Of Regents, The University Of Texas System
Austin, TX 78701 (US)

(72) Inventors:
  • YEE, Cassian
    Houston, Texas 77030 (US)
  • PAN, Ke
    Houston, Texas 77030 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE